Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

D’Alessio, Antonio; Angela Maria Fulgenzi, Claudia; Nishida, Naoshi; Schönlein, Martin; von Felden, Johann; Schulze, Kornelius; Wege, Henning; E. Gaillard, Vincent; Saeed, Anwaar; Wietharn, Brooke; Hildebrand, Hannah; Wu, Linda; Ang, Celina; U. Marron, Thomas; Weinmann, Arndt; R. Galle, Peter; Bettinger, Dominik; Bengsch, Bertram; Vogel, Arndt; Balcar, Lorenz; Scheiner, Bernhard; Lee, Pei‐Chang; Huang, Yi‐Hsiang; Amara, Suneetha; Muzaffar, Mahvish; Rafeh Naqash, Abdul; Cammarota, Antonella; Personeni, Nicola; Pressiani, Tiziana; Sharma, Rohini; Pinter, Matthias; Cortellini, Alessio; Kudo, Masatoshi; Rimassa, Lorenza; J. Pinato, David

doi:10.1002/hep.32468

Public

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Shared by NobleBlocks on Apr 8, 2022 • 12:00 AM UTC

Authors:

Antonio D’Alessio

Claudia Angela Maria Fulgenzi

Naoshi Nishida

Abstract

Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function. Approach and Results In 216 patients with HCC who were c...

Discussions